What to track on a GLP‑1.
A GLP‑1 log can grow until it feels like a second job. The useful version is smaller: a dose, a site, a few symptoms, a weight if you weigh, and what is left in the box. Each item earns its place by answering a question your prescriber might ask.
Start with the dose
The first entry in any GLP‑1 log is the dose itself: the medication, the amount, the date and the time. That sounds obvious until a dose changes. A record that only says “took my shot” cannot show whether the weeks after a change were different from the weeks before it. A record with the amount can.
The label for your medication gives the form and the strengths it comes in. Ozempic® is a weekly pen, with a daily tablet form; Wegovy® is a weekly pen or a daily tablet; Zepbound® is a weekly pen, vial or KwikPen; Rybelsus® is a daily tablet. The form matters because the routine around it differs. A pill has a wait before food. A pen has a site and a needle. A vial has a volume and a syringe.
Record the form you actually used, not the form on the prescription. If a pharmacy supplies a different presentation, the log records that, because the change can explain a difference in how the week felt.
The medication name is worth recording in full, including the brand if there is one. “Semaglutide” can mean a weekly pen, a daily tablet or a compounded vial, and those are different routines. A prescriber reading “semaglutide 1 mg” may assume a pen when the record meant a tablet. The extra word prevents the wrong assumption.
If you switch from one form to another, start a new note rather than editing the old one. The old entries are the history of the old routine. The new entries are the history of the new one. Keeping both is more useful than a single merged line.
Symptoms, in your own words
The labels list common adverse reactions in percentages: nausea, diarrhea, vomiting, constipation, abdominal pain, fatigue, headache, injection-site reactions and others. A trial percentage is not a description of your Tuesday. Write what happened in plain words, with a severity you can compare from week to week: mild, moderate or severe, and how long it lasted.
Two details make a symptom entry more useful. The first is timing: did it start the day of the dose, two days later, or after a change in dose? The second is what else was going on: a missed dose, a new food, a stomach bug, a travel day. Those details are not excuses. They are the context that helps a prescriber tell a medication effect from something unrelated.
A symptom diary with a fixed list can be easier to fill in than a blank page, as long as it leaves room for “something else.” The point is to notice a pattern, not to score every day.
Patterns are more useful than totals. “Nausea on the first two days of every step” is a pattern. “Nausea score 6/10” without a date is a number. If you use a scale, anchor it to something you can remember: mild meant you noticed it but ate normally; moderate meant you changed a meal; severe meant you stayed home or called for advice. The anchors make the entries comparable from month to month.
Weight, if you weigh
Weight is optional. Some people weigh daily, some weekly, some not at all. If you do weigh, the number is more useful as a trend than as a single reading. Day-to-day changes are mostly water, glycogen and the contents of the gut, which is why a 7‑day average is steadier than the last reading.
The ADA’s Standards of Care for 2026 recommend monitoring obesity-related anthropometric measurements at least annually, and at least every 3 months during active weight management treatment. That is the clinical schedule, not a rule for your bathroom scale. A log that holds a few months of readings can answer the appointment question “what direction has this been going?” without turning every morning into a verdict.
If you track waist or another measurement, record it the same way each time: same tape, same place, same posture. A changing method looks like a changing body. A short note about the method, written once, saves you from wondering later whether the tape was in the same place, and it makes the trend legible to someone else. The number is only half the record; the method is the other half, and it takes one line to write at the top of the page.
Supply, questions and the shortest version
Supply is the part people forget until the last pen is empty. A simple count of pens, vials or packs left, plus the date you started the current one, gives you a refill warning you can act on. The labels also set limits on how long an in-use pen or vial can stay out of the refrigerator; those limits belong beside the count, not in a drawer of leaflets.
Keep a short list of questions for the next appointment. “The nausea was worse on the second week of this dose” is easier to ask about when the date is in front of you. So is “I missed a dose and was not sure what the label meant.”
The shortest version that works is three entries: the dose, a one-line check‑in, and a supply count. Max HP keeps those three together and adds the site and weight if you use them. It does not ask for a food diary, a mood score or a prediction. The record is there to answer questions, not to create a new task.
Questions
- What are the most important things to track on a GLP‑1?
- The dose and date, the injection site if you inject, any symptoms with their timing and severity, weight if you weigh, and how much supply is left. Those five answer most of the questions that come up at an appointment.
- Do I need to track food or calories?
- No. A GLP‑1 log does not need a food diary to be useful. If your prescriber asks for one, follow their instructions; otherwise, the dose and symptom record is the core.
- How often do I need to log?
- At each dose, plus a short check‑in when something changes. A daily weigh‑in is optional. The record is more likely to survive if it takes less than a minute on an ordinary day.
- What if I miss a few weeks of logging?
- Start again with the next dose. A gap is information too, and a prescriber can read a record that resumes. There is no need to reconstruct weeks you do not remember.
Sources
- American Diabetes Association, “Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026,” Diabetes Care 49, Supplement 1 (2026): S166–S182. Read 4 November 2026.
- Ozempic® (semaglutide) prescribing information, DailyMed. Revised May 2026. Read 3 November 2026.
- Wegovy® (semaglutide) prescribing information, DailyMed. Revised June 2026. Read 3 November 2026.
- Zepbound® (tirzepatide) prescribing information, DailyMed. Revised August 2026. Read 3 November 2026.
- Rybelsus® and Ozempic® tablets prescribing information, DailyMed. Revised January 2026. Read 3 November 2026.